Bristol-Myers Squibb: Index

Global Reporting Initiative Content Index

The Bristol-Myers Squibb sustainability website is a GRI-based report. We believe we are among the first companies to issue a GRI-based report, following the criteria in the Global Reporting Initiative (GRI) 2006 G3 Sustainability Reporting Guidelines.

The GRI Application Level grid (below) is included in this report to support our self-declaration of this report at Application Level B+. An independent third-party review of this website confirms that it meets the content and quality requirements of GRI G3 Application Level B+.

Report Application Level	C	B	A
	(C+ = Report Externally Verified)	(B+ = Report Externally Verified)	(A+ = Report Externally Verified)
G3 Profile Disclosures	Report on: 1.1, 2.1-2.10, 3.1-3.8, 3.10-3.12, 4.1-4.4, 4.14-4.15	Report on all criteria listed for Level C plus: 1.2, 3.9, 3.13, 4.5-4.13, 4.16-4.17	Same as requirement for Level B
G3 Management Approach Disclosures	Not Required	Management Approach Disclosures for each Indicator Category	Management Approach Disclosures for each Indicator Category
G3 Performance Indicators and Sector Supplement Performance Indicators	Report on a minimum of 10 Performance Indicators, including at least one from each of: social, economic, and environmental	Report on a minimum of 20 Performance Indicators, including at least one from each of: economic, environmental, human rights, labor, society, product responsibility	Respond on each core G3 and Sector Supplement indicator with due regard to the materiality principle by either: a) reporting on the indicator or b) explaining the reason for its omission

We are interested in your feedback. Please send us your comments on the GRI Content Index below and our self-declaration as a GRI-based report.

The following index is designed for stakeholders who are familiar with the Global Reporting Initiative (GRI) 2006 G3 Sustainability Reporting Guidelines. For each G3 performance indicator below, we include a link to the pertinent section of the Bristol-Myers Squibb sustainability website.

GRI Indicator	Description	Location within www.bms.com/sustainability
1. Strategy and Analysis
1.1	Statement from senior decision-maker	CEO Message
1.2	Description of key impacts, risks, and opportunities	Sustainability Issues
2. Organizational Profile
2.1	Organization's name	Key Facts
2.2	Major products	Key Facts
2.3	Operational structure and major divisions	Key Facts Our Partners and Leadership
2.4	Location of headquarters	New York, New York, USA
2.5	Countries of operation	Economic Responsibility Economic Performance Facility Information
2.6	Nature of ownership	Key Facts Economic Responsibility
2.7	Markets served including geographic breakdown/sectors served/customers	Economic Responsibility Economic Performance
2.8	Scale of organization including number of employees, nets sales/revenues, total capitalization	Key Facts Economic Performance Key Performance Indicators 2011 Annual Report, pdf page 32
2.9	Significant changes during reporting period	A Brief History of Bristol-Myers Squibb
2.10	Awards	Awards & Recognition
3. Report Parameters
3.1	Reporting period	About this Report– Reporting Period and Scope
3.2	Date of previous report	About this Report– Reporting Period and Scope
3.3	Reporting cycle	About this Report– Reporting Period and Scope
3.4	Contact point	About this Report– Contact Point for Questions
3.5	Process for defining report content	About this Report– Defining Report Content Sustainability Issues Stakeholder Engagement
3.6	Boundary of the report	About this Report– Reporting Period and Scope
3.7	Limitations on the scope or boundary of the report	About this Report– Reporting Period and Scope
3.8	Basis for reporting on joint ventures, etc.	About this Report– Reporting Period and Scope
3.9	Data measurement techniques and bases of calculations including assumptions	Process for Data Collection Environmental Performance Energy Climate Change and Greenhouse Gas Emissions Other Air Emissions Waste Safety
3.10	Restatements of information	About this Report– Changes in Reporting
3.11	Significant changes from previous reporting periods	About this Report– Changes in Reporting
3.12	GRI Content Index table	Global Reporting Initiative Content Index
3.13	Policy and practice for seeking independent assurance for report	About this Report Verification

4. Governance, Commitments & Engagement
4.1	Governance structure including committees	Corporate Governance Board of Directors Committee Charters
4.2	Indicate whether chair of highest governance body is also an executive officer	Key Facts Corporate Governance Guidelines Corporate Governance – Organization Board of Directors
4.3	Percent of independent directors	Corporate Governance Guidelines Corporate Governance – Board of Directors
4.4	Mechanisms for shareholders and employees to provide recommendations/direction to highest governance body	Codes of Conduct Third Party Standards Contact Our Directors Dialogue
4.5	Linkage between compensation and organization’s performance for members of highest governance body/senior executives	Corporate Governance Guidelines Corporate Governance – Compensation and Non-Financial Goals Compensation and Management Development Committee Charter
4.6	Process for the Board to ensure conflicts of interest are avoided	Corporate Governance Guidelines
4.7	Processes for determine qualifications and expertise for guiding strategy	Committee on Directors and Corporate Governance Management System Components
4.8	Mission and values statements, codes of conduct, principles relevant to economic, environmental and social performance, and status of implementation	Codes of Conduct Third Party Standards Management Systems
4.9	Procedures of highest governance body for overseeing economic, environmental and social performance including compliance, codes of conduct	Corporate Governance - Organization Organization Management Systems Third Party Standards
4.10	Processes for evaluating performance of governance body with respect to economic, environmental and social performance	Corporate Governance Guidelines Management System Components
4.11	Explanation of how precautionary approach/principle is addressed by organization	Systems for Managing Risk Third Party Standards
4.12	Externally developed, voluntary economic, environmental, and social charters, sets of principles, or other initiatives	Overarching Policies– Voluntary standards
4.13	Significant memberships in associations and/or advocacy organizations	Stakeholder Engagement– Business association memberships
4.14	List of stakeholder groups	Stakeholder Engagement World Health Organization Access to Medicines UN Global Compact Pharmaceutical Supply Chain Initiative Together on Diabetes What We Support Recent Grants Drug Donations and Other Philanthropic Efforts Disaster Relief & Product Donations Bristol-Myers Squibb Foundation Reducing Health Disparities Cancer in Europe Hepatitis in Asia HIV/AIDS Africa Mental Health in US Our Partners Political Contributions Investor Relations Our Communities Worldwide Facilities Workplace Policies Bristol-Myers Squibb engages with numerous socially-responsible investment firms and rating organizations to understand and respond to areas of interest, including, but not limited to: Access to Medicines, Bloomberg, Carbon Disclosure Project, Corporate Responsibility, Dow Jones Sustainability Index, EIRIS, Goldman Sachs Sustain, Interfaith Center on Corporate Responsibility, Maplecroft, Newsweek, oekom, and Sustainalytics.
4.15	Basis for identification and selection of stakeholders with whom to engage	Stakeholder Engagement Partnering Areas of Interest Our Process Our Partners How to Apply for Bristol-Myers Squibb Foundation Grants Political Contributions Clinical Research Grants Corporate Giving Independent Medical Education
4.16	Approaches to stakeholder engagement, including frequency and type	Stakeholder Engagement
4.17	Key issues raised through stakeholder engagement and how organization has responded	Position on Key Issues Stakeholder Engagement
Economic Performance Indicators
	Management approach	Economic Responsibility– Management Approach Market Presence Indirect Benefits
EC1	Direct economic value generated and distributed	2011 Annual Report, pdf pages 30-33 (Consolidated Financial Statements) 2011 Annual Report, pdf pages 52-53 (Fair Value Measurement) 2011 Annual Report, pdf page 57 (Accrued employee compensation and benefits) Grants & Giving Economic Performance Key Performance Indicators Benefits Shareholder Value
EC2	Financial implications and other risks and opportunities due to climate change	Material issues –Energy and Water Risk/Opportunity related to Climate Change
EC3	Coverage of the defined benefit plan obligations	2011 Annual Report, pdf pages 60 - 65 (Pension, Postretirement & Postemployment Liabilities)
EC8	Development and impact of infrastructure investments and services provided for public benefit	Philanthropy, Foundation and Corporate Philanthropy
EC9	Indirect impacts	Indirect Impacts
Environmental Performance Indicators
	Management approach	Environmental Performance– Management Approach Overarching Policies
EN3	Direct energy consumption	Direct Energy Consumption (Gigajoules) Light Fuel Oil 2010: 176,000 2011: 236,000 Natural Gas 2010: 4,207,000 2011: 4,109,000 Propane (LPG) 2010: 347,000 2011: 273,000 Energy Conservation Sustainability Issues Energy and Water Key Performance Indicators Solar panels installed at our Anagni and Hopewell facilities supply renewable energy. In 2010 and 2011, we generated 405 and 342 gigajoules of energy through these renewable energy sources, respectively. Using natural gas, we generated 1.6 million gigajoules of combined steam and electricity at Bristol-Myers Squibb facilities on site in 2011.
EN4	Indirect energy consumption	Energy Conservation Sustainability Issues Energy and Water Key Performance Indicators Greenhouse Gas Emissions In 2011, our Munich, Germany facility specified purchase of a percentage of energy from their supplier be from renewable sources. This resulted in purchase of 1,440 gigajoules of energy from renewable sources in 2011, out of a total consumption of 11.5 million gigajoules companywide. Amounts of renewable energy sourced from other energy providers are not available at this time.
EN5	Energy saved due to conservation and efficiency improvements	Energy Conservation Sustainability Issues Energy and Water
EN7	Initiatives to reduce indirect energy consumption	Energy Conservation Sustainability Issues Energy and Water
EN8	Total water withdrawal	Water Use Sustainability Issues Energy and Water Key Performance Indicators
EN9	Water sources significantly affected by withdrawal of water.	Water Use
EN13	Habitats protected or restored	Biodiversity and Land Use
EN14	Strategies, current actions, and future plans for managing impacts on biodiversity	Biodiversity and Land Use
EN16	Direct and indirect greenhouse gas emissions	Climate Change and Greenhouse Gas Emissions Key Performance Indicators
EN17	Other relevant indirect greenhouse gas emissions by weight.	Climate Change and Greenhouse Gas Emissions Key Performance Indicators
EN18	Initiatives to reduce greenhouse gas emissions	Climate Change and Greenhouse Gas Emissions Energy Conservation
EN19	Emissions of ozone-depleting substances	Other Air Emissions
EN20	NO, SO, and other air emissions	Other Air Emissions
EN21	Water discharge	Wastewater Effluents
EN22	Waste	Waste Key Performance Indicators
EN23	Significant spills	Compliance and Remediation
EN24	Hazardous waste	Goals and Key Indicators
EN26	Initiative to mitigate environmental impacts of products	Product Stewardship Wastewater Effluents
EN28	Compliance	Compliance and Remediation
EN29	Transport	Transportation
Social Performance Indicators
	Management approach - LA	Social Progress Management Approach
LA1	Total workforce	Diversity and Work/Life Integration Key Indicators
LA3	Benefits	Benefits Program Highlights, Wages and Benefits
LA6	Worker input on health and safety	Safety
LA7	Health and safety rates	Safety
LA8	Programs to assist employees, families, or community members regarding serious diseases	Health and Wellness
LA11	Skills management and lifelong learning	Benefits Listing Developing our People Education and Training
LA13	Diversity	Diversity and Work/Life Integration
	Management approach - HR	Suppliers Workplace Policies Diversity & Inclusion Supplier Diversity Intellectual Property
HR5	Freedom of association	Overarching Policies UN Global Compact
HR6	Operations having significant risk for incidents of child labor	Workplace Policies - Labor
HR7	Operations having significant risk for incidents of forced labor	Workplace Policies - Labor
	Management approach - SO	Our Communities Overarching Policies Standards of Business Conduct & Ethics Social Progress Compliance & Ethics
SO2	Corruption risk	Compliance & Ethics Third Party Standards
SO3	Anti-corruption training	Compliance & Ethics
SO5	Public policy development and lobbying	Political Contributions
SO6	Total value of contributions to political parties, politicians, and related institutions	Political Contributions
SO8	Significant fines/sanctions	SEC Filings EHS Compliance & Remediation 2011 Annual Report, pdf page 92
	Management approach – PR	Product Responsibility Data Privacy
PR1	Product and service health and safety impact assessment	Sustainability 2015 Goals Sharps Management Plan
PR2	Product and service health	Clinical Trials Disclosure
PR3	Type of product and service information and safety compliance	Products
PR5	Practices related to consumer satisfaction	Compliance & Ethics Code
PR6	Program for adherence to laws, standards, and voluntary codes related to marketing communications	Product Responsibility Compliance and Ethics Compliance & Ethics Code Endorsement of Pharma Codes/Principles
PR9	Significant fines concerning provision and use of products and services	2011 Annual Report, page 92

Note: In addition to the locations listed in this table, many of the indicators are summarized in the Key Performance Indicators section of this website. For more help in locating sustainability topics, see the site Index.